Antipsychotic reexposure and recurrent pneumonia in schizophrenia: A nested case-control study

Journal of Clinical Psychiatry

Volumn 77, Issue 1, 2016, Pages 60-66

  Hung, Galen Chin Lun ^a,f   Liu, Hsing Cheng ^a,d   Yang, Shu Yu ^a,c   Pan, Chun Hung ^a,g   Liao, Ya Tang ^b   Chen, Chiao Chicy ^a,d,e   Kuo, Chian Jue ^a,d  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG REEXPOSURE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENT DISEASE; RECURRENT PNEUMONIA; SCHIZOPHRENIA; TAIWAN; TREATMENT DURATION; ADOLESCENT; AGED; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; FACTUAL DATABASE; MIDDLE AGED; RISK FACTOR; SEXUAL DEVELOPMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLOZAPINE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84957806798     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09301     Document Type: Article

References (31)

1. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087. doi:10.101/archpsyc.63.10.1079 PubMed
2. Hartling L, Abou-Setta AM, Dursun S, et al. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157(7):498-511. doi:10.7326/03-4819-157-7-20121020-0525 PubMed
3. Trifirò G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418-425, W139-40. doi:10.7326/03-4819-152-7-20104060-06 PubMed
4. Kuo CJ, Yang SY, Liao YT, et al. Secondgeneration antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013;39(3):648-657. doi:10.1093/schbul/sbr202 PubMed
5. Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661-666. doi:10.1/j.1532-5415.207.01625.x PubMed
6. Yang SY, Liao YT, Liu HC, et al. Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psychiatry. 2013;74(1):e79-e86. doi:10.408/JCP.12m07938 PubMed
7. Public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances, April 11, 2005. US Food and Drug Administration Web site. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171. Updated August 16, 2013.
8. Chen YH, Lin HC, Lin HC. Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr Bull. 2011;37(5):1088-1094. doi:10.1093/schbul/sbq019 PubMed
9. Liao YT, Yang SY, Liu HC, et al. Cardiac complications associated with short-term mortality in schizophrenia patients hospitalized for pneumonia: a nationwide case-control study. PLoS ONE. 2013;8(7):e70142. doi:10.13
10. Garcia-Vidal C, Carratalà J, Fernández-Sabé N, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15(11):1033-1038. doi:10.1/j.1469-0691.209.02918.x PubMed
11. Seppälä N, Kovio C, Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs. 2005;19(12):1049-1055. doi:10.2165/023210-20519120-06 PubMed
12. Krivoy A, Malka L, Fischel T, et al. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol. 2011;26(6):311-315.
13. Leucht S, Corves C, Arbter D, et al. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736 (08) 61764-X PubMed
14. Nielsen J, Correll CU, Manu P, et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):603-613, quiz 613. doi:10.408/JCP.12r08064 PubMed
15. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatry. 2012;73(2):252-254. doi:10.408/JCP.1l07467 PubMed
16. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25-35. doi:10.2165/023210-20721010-03 PubMed
17. Weller M, Kornhuber J. Clozapine rechallenge after an episode of 'neuroleptic malignant syndrome'. Br J Psychiatry. 1992;161(6):855-856. doi:10.192/bjp. 161.6.85 PubMed
18. Eurich DT, Lee C, Marrie TJ, et al. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57(8):1138-1144. doi:10.1093/cid/cit472 PubMed
19. WHO Collaborating Centre for Drug Statistic Methodology. ATC Index With DDDs. Oslo, Norway: WHO; 2009.
20. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048.
21. Lee ET. Statistical Methods for Survival Data Analysis. New York, NY: John Wiley and Sons; 1992.
22. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia, PA: WB Saunders; 1985.
23. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;79:516-524.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. doi:10.1097/01.mlr.0182534.19832.83 PubMed
25. Quail JM, Lix LM, Osman BA, et al. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res. 2011;11(1):146. doi:10.186/1472-6963-1-146 PubMed
26. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965-971. doi:10.17/0269810810320 PubMed
27. Humbert-Claude M, Davenas E, Gbahou F, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl). 2012;220(1):225-241. doi:10.107/s0213-01-2471-5 PubMed
28. Maddalena AS, Fox M, Hofmann M, et al. Esophageal dysfunction on psychotropic medication: a case report and literature review. Pharmacopsychiatry. 2004;37(3):134-138. doi:10.105/s-204-81893 PubMed
29. Leung JG, Puri NV, Jacobson MJ. Immediaterelease oxybutynin for the treatment of clozapine-induced sialorrhea. Ann Pharmacother. 2011;45(9):e45. doi:10.1345/aph.1Q270 PubMed
30. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-167. doi:10.1056/NEJM19307153290303 PubMed
31. Fabrazzo M, Esposito G, Fusco R, et al. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology (Berl). 1996;124(1-2):197-200.